Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Hemorrhage 13Neoplasms 7Leiomyoma 6Breast Neoplasms 6Hematologic Neoplasms 4Thrombocytopenia 3Postoperative Hemorrhage 3Meningioma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Seroma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Myofibroma 2Head and Neck Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Bone Neoplasms 2Blood Loss, Surgical 2Wrist Fractures 1Urologic Diseases 1Urinary Retention 1Thromboembolism 1Skin Neoplasms 1Seizures 1Sarcoma 1Recurrence 1Postoperative Complications 1Polyposis, Gastric 1Pituitary Neoplasms 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × Tranexamic Acid × Clear all
NCT01869413 2022-10-04

TACT

Ottawa Hospital Research Institute

Phase 2/3 Completed
354 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04555343 2021-11-05

Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention

Fraser Health

Phase 1/2 Completed
14 enrolled
Genitourinary

Urinary Bladder Neoplasms, Hematuria, Prostatic Neoplasms, Urologic Diseases, Urinary Retention, Patient Satisfaction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡